CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma

Radiology

Volumn 280, Issue 1, 2016, Pages 271-280

  Liu, Ying ^a,b   Kim, Jongphil ^b   Qu, Fangyuan ^a   Liu, Shichang ^a   Wang, Hua ^a,b   Balagurunathan, Yoganand ^b   Ye, Zhaoxiang ^a   Gillies, Robert J ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IODINATED CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; ASIAN; CANCER GRADING; CANCER SIZE; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EGFR GENE; EMPHYSEMA; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG FIBROSIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PLEURA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; ADENOCARCINOMA; DIAGNOSTIC IMAGING; GENETICS; LUNG; LUNG TUMOR; MIDDLE AGED; MUTATION; PROCEDURES; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84975222065     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016151455     Document Type: Article

References (29)

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma: Executive summary. Proc Am Thorac Soc 2011;8(5):381-385.
2. Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med 2014;138(10):1353-1357.
3. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol 2013;8(1):52-61.
4. Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 2013;8(4):461-468.
5. Shim HS, Lee H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011;135(10):1329-1334.
6. Choi CM, Kim MY, Lee JC, Kim HJ. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy. Radiology 2014;270(2):574- 582.
7. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-246.
8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 2011;12(8):735-742.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-132.
10. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290(16):2149-2158.
11. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99(5):929-935.
12. Chu H, Zhong C, Xue G, et al. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncol Rep 2013;30(5):2311-2315.
13. Liu J, Zhao R, Zhang J, Zhang J. ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens. J Cancer Res Clin Oncol 2015;141(2):221-227.
14. Lee Y, Lee HJ, Kim YT, et al. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: Relationship with epidermal growth factor receptor protein expression status and survival. Korean J Radiol 2013;14(2):375-383.
15. Lee HJ, Kim YT, Kang CH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: Relationship with CT characteristics and histologic subtypes. Radiology 2013;268(1):254-264.
16. Sugano M, Shimizu K, Nakano T, et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep 2011;26(5):1205-1211.
17. Hsu KH, Chen KC, Yang TY, et al. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol 2011;6(6):1066-1072.
18. Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 2006;1(5):413-416.
19. Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 2016;26(1): 32-42.
20. Zhou JY, Zheng J, Yu ZF, et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol 2015;25(5):1257-1266.
21. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 2012;4(4):128-134.
22. Zwirewich CV, Vedal S, Miller RR, Müller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology 1991;179(2):469-476.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44(3):837-845.
24. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 2013;30(3):645.
25. Usui K, Ushijima T, Tanaka Y, et al. The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulm Med 2011;2011:290132.
26. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012;18(7):1947-1953.
27. Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7(2): 323-330.
28. Sekine A, Tamura K, Satoh H, et al. Prevalence of underlying lung disease in smokers with epidermal growth factor receptormutant lung cancer. Oncol Rep 2013;29(5): 2005-2010.
29. Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29(24):3316-3321.